# Title

 Food and Drugs. PART 511â€”NEW ANIMAL DRUGS FOR INVESTIGATIONAL USE


# ID

 CFR-2018-title21-vol6.Pt. 511


# Structured Analysis Summary

| Type        | Values                                                                                                                                                         |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'maximum', 'after', 'minimum', 'prior to']                                                                                                |
| Duration    | ['2.0 year']                                                                                                                                                   |
| Condition   | ['until', 'unless', 'where', 'if not', 'subject to', 'when', 'if']                                                                                             |
| Entities    | ['United States', 'Agriculture', 'New Animal Drug', 'Food', 'Rockville, MD', 'New', 'Health', 'Investigator', 'U.S.C', 'Sponsor', 'Notice', 'U.S. Department'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                         |
|:--------------|:----------------------------------------------------------------------------------------------------------------|
| after         | and delivery for a period of 2 years after  such shipment and delivery.                                         |
| within        | the carton label and other labeling on or within the package from which the new animal drug                     |
| after         | and delivery for a period of 2 years after  such shipment and delivery.                                         |
| prior to      | (i) The identity of the new animal drug. prior to                                                               |
| maximum       | (c) The  maximum daily dose(s) to be administered to a given                                                    |
| maximum       | (c) The  maximum daily dose(s) to be administered to a given                                                    |
| maximum       | of food derived from animals treated at the maximum levels with the minimum withdrawal periods, if any,         |
| minimum       | animals treated at the maximum levels with the minimum withdrawal periods, if any, specified in accordance with |
| maximum       | that food derived from animals treated at the maximum levels and with the minimum withdrawal periods, if        |
| minimum       | treated at the maximum levels and with the minimum withdrawal periods, if any, specified in accordance with     |
| after         | be retained by the investigator for 2 years after the termination of the investigation or approval of           |
| after         | all reports received from investigators for 2 years after the termination of the investigation or approval of   |
| prior to      | States or the ultimate consignee, which person has, prior to such shipments and deliveries, informed FDA of his |
| after         | eligible to receive test articles under this part. after                                                        |
| after         | (4) If the Commissioner determines,  after the unreliable data submitted by the investigator are                |
| before        | shall have an opportunity for a regulatory hearing before FDA under part 16 on the question of                  |
| after         | (5) If the Commissioner determines,  after the unreliable data submitted by the investigator are                |
| before        | shall have an opportunity for a regulatory hearing before FDA pursuant of part 16 of this chapter               |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.0 year   | (3) The person who introduced such shipment or who delivered the new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the expert or expert organization to whom the new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery.                                                                        |
| 2.0 year   | (3) The person who introduced such shipment or who delivered the new animal drug or animal feed containing a new animal drug for introduction into interstate commerce shall maintain adequate records showing the name and post office address of the investigator to whom the new animal drug or animal feed containing a new animal drug is shipped and the date, quantity, and batch or code mark of each shipment and delivery for a period of 2 years after such shipment and delivery. |
| 2.0 year   | Copies of all records of the investigation shall be retained by the investigator for 2 years after the termination of the investigation or approval of a new animal drug application.                                                                                                                                                                                                                                                                                                         |
| 2.0 year   | (8) The sponsor:                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |             (i) Shall retain all reports received from investigators for 2 years after the termination of the investigation or approval of a new animal drug application and make such reports available to a duly authorized employee of the Department for inspection at all reasonable times.                                                                                                                                                                                              |


## Condition

| Condition   | Context                                                                                                                                   |
|:------------|:------------------------------------------------------------------------------------------------------------------------------------------|
| if          | section 512 (a) and (m) of the act if  it is labeled as follows:                                                                          |
| if          | from section 512(a) and (m) of the act if all the following conditions are met: (1) The                                                   |
| if          | forth in part 58 of this chapter, or, if the study was not conducted in compliance with                                                   |
| if not      | approximate number of animals to be treated (or if not available, the amount of new animal drug to                                        |
| if          | accordance with the provisions prescribed in this section. if                                                                             |
| if          | administration, method(s) of administration, and proposed withdrawal time, if  any.                                                       |
| if          | and address of the contract research organization, ident if ication of the clinical study, and a listing                                  |
| when        | granted under the provisions of this section and when the following specified conditions are met, except that                             |
| when        | be exempt from the requirements of this section when U.S. Department of Agriculture approval has been obtained                            |
| if          | the maximum levels with the minimum withdrawal periods, if  any, spec                                                                     |
| if          | maximum levels and with the minimum withdrawal periods, if  any, spec                                                                     |
| where       | The name and location of the packing plant where the animals will be processed, except that this                                          |
| until       | commercially distribute nor test-market the new animal drug until a new animal drug application is approved pursuant                      |
| if          | animal drug is shipped directly to a scient if ic institution with adequate facilities and qual                                           |
| if          | option of the investigator, in an informal conference. if                                                                                 |
| if          | information, including any explanation presented by the investigator, if the Commissioner determines that the investigator has repeatedly |
| subject to  | be ineligible to receive FDA-regulated test articles is subject to examination to determine whether the investigator has submitted        |
| if          | to continue the investigation, the Commissioner will not if y the sponsor, who shall have an opportunity                                  |
| if          | which the data were submitted cannot be just if ied, the Commissioner will proceed to withdraw approval                                   |
| when        | of this section may be reinstated as eligible when the Commissioner determines that the investigator has presented                        |
| if not      | Any such transfer shall be in writing and,  if not all obligations are transferred, shall describe each of                                |
| subject to  | chapter applicable to this obligation and shall be subject to the same regulatory action as a sponsor for                                 |
| subject to  | as described in section 572 of the act, subject to  the provisions of &#167;&#8201;516.125 of this chapter.                               |
| unless      | The sponsor does not actually conduct the investigation  unless  the sponsor is a sponsor-investigator.                                   |


## Entities

| Entities        | Context                                                                                                                                    |
|:----------------|:-------------------------------------------------------------------------------------------------------------------------------------------|
| Food            | Food  and Drugs.                                                                                                                           |
| New             | New animal drugs for investigational use exempt from section                                                                               |
| New             | (a)  New animal drugs for tests in vitro and in                                                                                            |
| New             | (b)  New  animal drugs for clinical investigation in animals.                                                                              |
| New Animal Drug | a &#8220;Notice of Claimed Investigational Exemption for a New Animal Drug &#8221; including a signed statement containing the following   |
| U.S.C           | regulated under the viruses, serums, toxins statute (21 U.S.C ., chapter V, sec.                                                           |
| U.S. Department | exempt from the requirements of this section when U.S. Department of Agriculture approval has been obtained as provided                    |
| Agriculture     | requirements of this section when U.S. Department of Agriculture approval has been obtained as provided in 9                               |
| United States   | is imported or offered for importation into the United States for clinical investigational use in animals, it shall                        |
| United States   | is imported or offered for importation into the United States for clinical investigational use in animals, it shall                        |
| Notice          | &#8220; Notice (s) of Claimed Investigational Exemption for a New                                                                          |
| New Animal Drug | &#8220;Notice(s) of Claimed Investigational Exemption for a  New Animal Drug &#8221; and requests for authorization to use investigational |
| Health          | food should be addressed to the Department of Health and Human Services, Food and Drug Administration, Center                              |
| Rockville, MD   | Administration, Center for Veterinary Medicine, 7500 Standish Pl., Rockville, MD  20855.                                                   |
| Investigator    | Investigator means an individual who actually conducts a clinical                                                                          |
| Sponsor         | Sponsor means a person who takes responsibility for and                                                                                    |


